Emergex Vaccines

The company's business model is centered on the development and eventual commercialization of its proprietary vaccine and immunotherapy candidates. Gylden is pioneering synthetic T-cell priming vaccines designed to mimic the body's natural cellular immune response. This approach aims to provide broad, long-lasting protection against viral and bacterial infections by priming CD8+ T-cells to recognize and destroy infected cells. The vaccines are 100% synthetic, allowing for rapid and cost-effective manufacturing without the need for biological components. Delivery is achieved through a microneedle array patch, designed for easy administration and stability at room temperature, eliminating the need for a cold chain. The company's initial focus is on infectious diseases such as Dengue Fever, universal influenza, and coronaviruses. Its pipeline also includes candidates for intracellular bacterial infections, migraine, cardiometabolic disorders, and cancer immunotherapy.

Professor Thomas Rademacher, the co-founder and CEO, is a serial entrepreneur and an Emeritus Professor of Molecular Medicine at University College London with a background in molecular medicine and glycobiology. Co-founder and COO Storme Moore-Thornicroft has a background in corporate and business strategy. The company has secured approximately $30 million in funding over six rounds, with a notable Series A round of $11 million in January 2020 led by Vickers Venture Partners. In October 2022, the company acquired the assets of Zosano Pharma, including its microneedle array patch technology and manufacturing capabilities.